{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-25-000012","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.650468+00:00","generated_at":"2026-05-28T03:06:47.021856+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Castle Biosciences expects 2024 revenue at least $330M (≥50% growth); Medicare non-covers DecisionDx-SCC","bullets":["Full-year 2024 revenue expected to meet or exceed top of guidance range $320-330M, at least 50% growth over 2023.","Delivered 96,071 total test reports in 2024, up 36% YoY; TissueCypher Barrett's Esophagus test grew 130%.","Year-end 2024 cash, cash equivalents and marketable securities approximately $293M.","Medicare contractor Novitas finalized non-coverage for DecisionDx-SCC test on January 9, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-25-000012","json":"https://secwatch.observer/filing/0001447362-25-000012.json","markdown":"https://secwatch.observer/filing/0001447362-25-000012.md","text":"https://secwatch.observer/filing/0001447362-25-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736225000012/0001447362-25-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736225000012/cstl-20250112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:06:47.021856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}